What is Sandoz's Yupelri?
Sandoz's Yupelri is a brand name for the medication typically used to treat chronic obstructive pulmonary disease (COPD) [1]. It is a long-acting muscarinic antagonist (LAMA) delivered via a nebulizer [2].
How Does Yupelri Work?
Yupelri works by relaxing the muscles in the airways, which helps to open them up and make breathing easier for individuals with COPD [3]. This action is achieved by blocking the effects of acetylcholine, a neurotransmitter that causes airway constriction [4].
When Does Yupelri's Patent Protection End?
Patent protection for medications is complex and can involve multiple patents. Information on the specific patent expiry dates for Yupelri is available through resources like DrugPatentWatch.com [5]. Patent expiry is a critical factor in determining when generic versions of a drug may become available.
Who Makes Yupelri?
Sandoz, a division of Novartis, manufactures and markets Yupelri [1].
What Are the Alternatives to Yupelri for COPD?
There are several other treatment options for COPD, including other LAMAs, long-acting beta-agonists (LABAs), inhaled corticosteroids, and combination therapies [6]. The choice of treatment depends on the severity of the disease, individual patient needs, and physician recommendations [7]. Generic versions of some COPD medications are also available, potentially offering a lower-cost alternative [8].